Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

Chen, Nan, Hao, Chuanming, Peng, Xiaomei, Lin, Hongli, Yin, Aiping, Hao, Li, Tao, Ye, Liang, Xinling, Liu, Zhengrong, Xing, Changying, Chen, Jianghua, Luo, Laimin, Zuo, Li, Liao, Yunhua, Liu, Bi-Cheng, Leong, Robert, Wang, Chunrong, Liu, Cameron, Neff, Thomas, Szczech, Lynda, Yu, Kin-Hung P.·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1813599

Cited by (584)

Items 101–200 of 584

Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches
Claudia Bozzini, Fabiana Busti, Giacomo Marchi, Alice Vianello, Claudio Cerchione, Giovanni Martinelli, Domenico Girelli · 2024 · Frontiers in Oncology
Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
Mengqiu Miao, Mengqiu Wu, Yuting Li, Lingge Zhang, Qianqian Jin, Jiaojiao Fan, Xinyue Xu, Ran Gu, Haiping Hao, Aihua Zhang et al. · 2022 · Frontiers in Pharmacology
Hypoxia and renal fibrosis
Stephanie Naas, Mario Schiffer, Johannes Schödel · 2023 · American Journal of Physiology-Cell Physiology
Anemia in chronic kidney disease
Maria Amélia Aguiar Hazin · 2020 · Revista da Associação Médica Brasileira
Treatment of anemia in difficult-to-manage patients with chronic kidney disease
Ritesh Raichoudhury, Bruce Spinowitz · 2021 · Kidney International Supplements
Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: A systematic review and meta‐analysis
Li Zheng, Jinhui Tian, Deping Liu, Yan Zhao, Xiaoyong Fang, Yatong Zhang, Yuming Liu · 2021 · British Journal of Clinical Pharmacology
The Hypoxia-Adenosine Link during Myocardial Ischemia—Reperfusion Injury
Wei Ruan, Xinxin Ma, In Hyuk Bang, Yafen Liang, Jochen Daniel Muehlschlegel, Kuang‐Lei Tsai, Tingting Mills, Xiaoyi Yuan, Holger K. Eltzschig · 2022 · Biomedicines
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
Emilia Scalzulli, Sara Pepe, Gioia Colafigli, Massimo Breccia · 2020 · Blood Reviews
Breakthrough science: hypoxia-inducible factors, oxygen sensing, and disorders of hematopoiesis
Gregg L. Semenza · 2021 · Blood
The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review
Yuanyuan Ma, Zhiyuan Zhou, Guo‐Yuan Yang, Jing Ding, Xin Wang · 2022 · Frontiers in Pharmacology
Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia
Sarah Parisi, Carlo Finelli, Antonietta Fazio, Alessia De Stefano, Sara Mongiorgi, Stefano Ratti, Alessandra Cappellini, Anna Maria Billi, Lucio Cocco, Matilde Y. Follo et al. · 2021 · International Journal of Molecular Sciences
Hypoxia-Inducible Factors and Diabetic Kidney Disease—How Deep Can We Go?
Alina Mihaela Stăniguț, Camelia Pana, Manuela Enciu, Mariana Deacu, Bogdan Cîmpineanu, Liliana Ana Tuta · 2022 · International Journal of Molecular Sciences
Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors
James P. Holt‐Martyn, Rasheduzzaman Chowdhury, Anthony Tumber, Tzu‐Lan Yeh, Martine I. Abboud, Kerstin Lippl, Christopher T. Lohans, Gareth W. Langley, William D. Figg, M.A. McDonough et al. · 2019 · ChemMedChem
Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research
Philip S. Macklin, Atsushi Yamamoto, Lisa Browning, Monika Hofer, Julie Adam, Christopher William Pugh · 2020 · The Journal of Pathology
Barrier integrity and chronic inflammation mediated by HIF-1 impact on intestinal tumorigenesis
Laura Robrahn, Long R. Jiao, Thorsten Cramer · 2020 · Cancer Letters
Roxadustat and Anemia of Chronic Kidney Disease
Joshua Kaplan · 2019 · New England Journal of Medicine
The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis
Qiyan Zheng, Huisheng Yang, Xinwen Fu, Yishan Huang, Ruojun Wei, Ya‐Hui Wang, Yuning Liu, Wei Jing Liu · 2020 · Nephrology Dialysis Transplantation
Anemia de las enfermedades crónicas: fisiopatología, diagnóstico y tratamiento
Ricardo de las Cuevas Allende, Lucía Díaz de Entresotos, Susana Conde Díez · 2020 · Medicina Clínica
Ophiocordyceps lanpingensis polysaccharides alleviate chronic kidney disease through MAPK/NF-κB pathway
Shubo Zhou, Yifeng He, Weiping Zhang, Yin Xiong, Li Jiang, Juan Wang, Xiuming Cui, Yuan Qu, Feng Ge · 2021 · Journal of Ethnopharmacology
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model
Peter A. C. Wing, Maria Prange‐Barczynska, Amy Rachael Cross, Stefania Crotta, Claudia Orbegozo Rubio, Xiaotong Cheng, James Michael Harris, Xiaodong Alan Zhuang, Rachel L. Johnson, Kathryn A. Ryan et al. · 2022 · PLoS Pathogens
When the Brain Yearns for Oxygen
Tristan Leu, Vera Schützhold, Joachim Fandrey, Katja B. Ferenz · 2019 · Neurosignals
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials
Kai‐Uwe Eckardt, Rajiv Agarwal, Youssef M.K. Farag, Alan G. Jardine, Zeeshan Khawaja, Mark J. Koury, Wei Feng Luo, Kunihiro Matsushita, Peter Andrew McCullough, Patrick S. Parfrey et al. · 2020 · Nephrology Dialysis Transplantation
Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis
Szu‐Yu Pan, Pei‐Zhen Tsai, Yu‐Hsiang Chou, Yu‐Ting Chang, Fan‐Chi Chang, Yen‐Ling Chiu, Wen‐Chih Chiang, Tien Hsu, Yung‐Ming Chen, Tzong‐Shinn Chu et al. · 2021 · Kidney International
A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease
Jun Chen, Xinyang Shou, Yanyan Xu, Lie Jin, Chaoyong Zhu, Xiaolan Ye, Ziwei Mei, Peipei Chen · 2023 · Aging
Hypoxia in chronic kidney disease: towards a paradigm shift?
Anna Faivre, Carsten C. Scholz, Sophie de Seigneux · 2020 · Nephrology Dialysis Transplantation
Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation
Huan Yang, Yong Jian Wu, Ming Cheng, Ming Zhang, Shaojun Liu, Shaojun Liu, Minmin Zhang · 2022 · Nephrology Dialysis Transplantation
Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease
Fangyuan Qian, Zuo‐Lin Li, Yudong Guo, Hanchao Gao, Lihua Gu, Kai Le, Chunming Xie, Bin Wang, Zhijun Zhang · 2019 · American Journal of Physiology-Renal Physiology
Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model
Kazuya Kabei, Yu Tateishi, Masayuki Shiota, Mayuko Osada‐Oka, Shunji Nishide, Junji Uchida, Tatsuya Nakatani, Shinji Matsunaga, Takehiro Yamaguchi, Shuhei Tomita et al. · 2019 · Journal of Pharmacological Sciences
Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis
Murilo Henrique Guedes, Camila R. Guetter, Lucas Henrique Olandoski Erbano, Andre G. Palone, Jarcy Zee, Bruce M. Robinson, Ronald L. Pisoni, Thyago Proença de Moraes, Roberto Pecoits‐Filho, Cristina Pellegrino Baena · 2020 · BMC Nephrology
Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis
Qiyan Zheng, Ya‐Hui Wang, Huisheng Yang, Luying Sun, Pingna Zhang, Xueqin Zhang, Jing Guo, Yuning Liu, Wei Jing Liu · 2022 · American Journal of Kidney Diseases
The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis
Kullaya Takkavatakarn, Theerachai Thammathiwat, Jeerath Phannajit, Pisut Katavetin, Kearkiat Praditpornsilpa, Somchai Eiam‐Ong, Paweena Susantitaphong · 2023 · Clinical Kidney Journal
Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
Junlan Yang, Jie Xing, Xiaodong Zhu, Xiaotong Xie, Lina Wang, Xiaoliang Zhang · 2023 · Frontiers in Endocrinology
VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
Jiayi Yang, Yuyi Ruan, Dan Wang, Jinjin Fan, Ning Luo, Huiting Chen, Xiaoyan Li, Wei Chen, Xin Wang · 2022 · Cell & Bioscience
Iron oxide nanoparticles carried by probiotics for iron absorption: a systematic review
Călina Ciont, Amalia Mesaroş, Oana Lelia Pop, Dan Cristian Vodnar · 2023 · Journal of Nanobiotechnology
Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients
Bin Wang, Qing Yin, Yu‐Chen Han, Min Wu, Zuo‐Lin Li, Yan Tu, Le‐Ting Zhou, Qing Wei, Hong Liu, Ri‐Ning Tang et al. · 2020 · Renal Failure
Lineage tracing analysis defines erythropoietin-producing cells as a distinct subpopulation of resident fibroblasts with unique behaviors
Keiichi Kaneko, Yuki Sato, Eiichiro Uchino, Naoya Toriu, Mayo Shigeta, Hiroshi Kiyonari, Shuichiro Endo, Shingo Fukuma, Motoko Yanagita · 2022 · Kidney International
Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia
Xiaojin Zhang, Yonghua Lei, Tianhan Hu, Yue Wu, Zhihong Li, Zhensheng Jiang, Changyong Yang, Lianshan Zhang, Qidong You · 2020 · Journal of Medicinal Chemistry
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku · 2020 · Current Opinion in Nephrology & Hypertension
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
Tadao Akizawa, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch · 2020 · Therapeutic Apheresis and Dialysis
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
Jonathan Barratt, Frank Dellanna, José María Portolés, Gabriel J. Choukroun, Luca De Nicola, James Young, Nada B. Dimkovic, Michael Reusch · 2023 · Advances in Therapy
ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
Lucia Del Vecchio, Roberto Minutolo · 2021 · Journal of Clinical Medicine
The 2019 Nobel Prize honors fundamental discoveries in hypoxia response
Moslehi, Javid, Rathmell, W. Kimryn · 2019 · Journal of Clinical Investigation
Metabolic rewiring controlled by HIF-1α tunes IgA-producing B-cell differentiation and intestinal inflammation
Xianyi Meng, Sahar Asadi-Asadabad, Shan Cao, Rui Song, Zhen Lin, Mohammed Safhi, Yi Qin, Estelle Tcheumi Tactoum, Regina Verena Taudte, Arif Bülent Ekici et al. · 2024 · Cellular and Molecular Immunology
Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
Jodie L. Babitt, Jeffrey S. Berns, Biykem Bozkurt, Rebecca S. Cheung Khedairy, Yarieli Cuevas, Emmanuel E. Effa, Michele Freerk Eisenga, Steven Fishbane, Yelena Z. Ginzburg, Volker H. Haase et al. · 2026 · Kidney International
The problem with transferrin saturation as an indicator of iron ‘sufficiency’ in chronic kidney disease
Anatole Besarab, Tilman Bernhard Drüeke · 2020 · Nephrology Dialysis Transplantation
Molecular regulation and function of FoxO3 in chronic kidney disease
Fangming Lin · 2020 · Current Opinion in Nephrology & Hypertension
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis
Jing Li, Qionghong Xie, Li You, Ningxin Xu, Chuan‐Ming Hao · 2020 · Pharmacological Research
Mitophagy mediated by HIF-1α/FUNDC1 signaling in tubular cells protects against renal ischemia/reperfusion injury
Wenjun Zhang, Chao Guo, Yi Li, Hao Wang, Huabing Wang, Yingying Wang, Tingting Wu, Huinan Wang, Gang Cheng, Jiangwei Man et al. · 2024 · Renal Failure
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma
Jiao Li, Kaimeng Huang, Meha Thakur, Fiona McBride, Ananthan Sadagopan, Daniel S Gallant, Prateek Khanna, Yasmin Nabil Laimon, Bingchen Li, Razan Assaad Mohanna et al. · 2025 · Nature Metabolism
Discoveries of how cells sense oxygen win the 2019 Nobel Prize in Physiology or medicine
Cheng‐Chia Lee, Chao‐Yi Wu, Huang‐Yu Yang · 2020 · Biomedical Journal
Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
Jay B. Wish · 2021 · Kidney International Reports
The construction of benzimidazo[2,1- a ]isoquinolin-6(5 H )-ones from N -methacryloyl-2-phenylbenzoimidazoles through radical strategies
Qing‐Qing Kang, Weikang Zhang, Guo‐Ping Ge, Hongxing Zheng, Wen‐Ting Wei · 2021 · Organic & Biomolecular Chemistry
Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
Tomas Ganz, Francesco Locatelli, Mustafa Arıcı, Tadao Akizawa, Michael Reusch · 2023 · Journal of Clinical Medicine
Iron and Sphingolipids as Common Players of (Mal)Adaptation to Hypoxia in Pulmonary Diseases
Sara Ottolenghi, Aı́da Zulueta, Anna Caretti · 2020 · International Journal of Molecular Sciences
Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat
Mei Tang, Changyu Zhu, Ting Yan, Yanglin Zhou, Qin Lv, Junlan Chuan · 2021 · Frontiers in Pharmacology
The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials
Basel Abdelazeem, Joseph Shehata, Kirellos Said Abbas, Nahla Ahmed El‐Shahat, Bilal Haider Malik, Pramod K. Savarapu, Mostafa M. Eltobgy, Arvind R. Kunadi · 2022 · PLoS ONE
Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
Ichiei Narita, Terumasa Hayashi, Shoichi Maruyama, Takao Masaki, Masaomi Nangaku, Tomoya Nishino, Hiroshi Satō, Tadashi Sofue, Takashi Wada, Enyu Imai et al. · 2022 · PLoS ONE
Analyses of the 2019 Nobel Prize in Physiology or Medicine: Molecular Machinery for Cellular Oxygen Level Response
Neyda Gilman · 2020 · Science & Technology Libraries
Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies
Yi Lv, Chen Ye, Zixi Li, Jiajia Ye, Huanhuan Cao, Chun Zhang, Huajun Jiang, Yumei Wang · 2025 · Diabetes/Metabolism Research and Reviews
Hypoxia-inducible factors not only regulate but also are myeloid-cell treatment targets
Lovis Kling, Adrian Schreiber, Kai‐Uwe Eckardt, Ralph Kettritz · 2020 · Journal of Leukocyte Biology
Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives
Murilo Henrique Guedes, Bruce M. Robinson, Gregorio T. Obrador, Allison Tong, Ronald L. Pisoni, Roberto Pecoits‐Filho · 2020 · Kidney360
Roxadustat (FG-4592) accelerates pulmonary growth, development, and function in a compensatory lung growth model
Victoria H. Ko, Lumeng Jenny Yu, Duy T. Dao, Xiaoran Li, Jordan D. Secor, Lorenzo Anez‐Bustillos, Bennet S. Cho, Amy Pan, Paul D. Mitchell, Hiroko Kishikawa et al. · 2020 · Angiogenesis
Iron Therapy in Chronic Kidney Disease: Days of Future Past
Kuo‐Hua Lee, Yang Ho, Der‐Cherng Tarng · 2021 · International Journal of Molecular Sciences
Roxadustat (FG‐4592) protects against ischaemia/reperfusion‐induced acute kidney injury through inhibiting the mitochondrial damage pathway in mice
Mei Zhang, Rong Dong, Jing Yuan, Jingjing Da, Yan Zha, Yanjun Long · 2021 · Clinical and Experimental Pharmacology and Physiology
Myeloid hypoxia-inducible factor HIF1A provides cardio-protection during ischemia and reperfusion via induction of netrin-1
Ka‐Lin Heck‐Swain, Jiwen Li, Wei Ruan, Xiaoyi Yuan, Yanyu Wang, Michael Koeppen, Holger K. Eltzschig · 2022 · Frontiers in Cardiovascular Medicine
HSP70 via HIF-1 α SUMOylation inhibits ferroptosis inducing lung cancer recurrence after insufficient radiofrequency ablation
Bin Peng, Xiean Ling, Tonghai Huang, Jun Wan · 2023 · PLoS ONE
Preconditioning strategies to prevent acute kidney injury
Martin Richard Späth, Felix Carlo Koehler, Karla Johanna Ruth Hoyer-Allo, Franziska Grundmann, Volker Rolf Burst, Roman‐Ulrich Müller · 2020 · F1000Research
Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease
M. Kanbay, Mustafa C. Bulbul, Sidar Çopur, B. Afşar, A. Sag, D. Siriopol, M. Kuwabara, Silvia Bădărau, A. Covic, A. Ortiz · 2020 · JN. Journal of Nephrology (Milano. 1992)
Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Ernane Souza, Katherine H. Cho, Shelby Thomas Harris, Naomi R. Flindt, Richard K. Watt, Amy Barton Pai · 2020 · Expert Opinion on Investigational Drugs
The journey from erythropoietin to 2019 Nobel Prize: Focus on hypoxia-inducible factors in the kidney
Szu‐Yu Pan, Wen‐Chih Chiang, Yung‐Ming Chen · 2020 · Journal of the Formosan Medical Association
If it’s not one thing, HIF’s another: immunoregulation by hypoxia inducible factors in disease
Ffion R Hammond, Amy Lewis, Philip M. Elks · 2020 · FEBS Journal
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease
Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku · 2021 · Expert Opinion on Pharmacotherapy
Macrophage migration inhibitory factor is regulated by HIF-1α and cAMP and promotes renal cyst cell proliferation in a macrophage-independent manner
Wajima Safi, Andre Kraus, Steffen Grampp, Johannes Schödel, Bjoern Buchholz · 2020 · Journal of Molecular Medicine
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Jing Liu, Yunhua Peng, Hiroyuki Inuzuka, Wenyi Wei · 2022 · Seminars in Cancer Biology
The role of roxadustat in chronic kidney disease patients complicated with anemia
Jie Liu, Fan Yang, Yousuf Abdulkarim Waheed, Shulin Li, Kun Liu, Xinglei Zhou · 2023 · The Korean Journal of Internal Medicine
Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients
Yuan Cheng, Qiong Xiang, Tao Cao, Fei Tang, Jia Chen, Dongli Qi, Haofei Hu, Haiying Song, Zheyi Chang, Ming Ku et al. · 2023 · Nephrology Dialysis Transplantation
Why Is Iron Deficiency/Anemia Linked to Alzheimer’s Disease and Its Comorbidities, and How Is It Prevented?
Karin Fehsel · 2023 · Biomedicines
Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial
Ping Zhang, Yan Jiang, Chunping Xu, Linghui Zhou, Hongguang Zheng, Deqiong Xie, Minghao Guo, Xiangyang Huang, Guoyuan Lu, Hongli Jiang et al. · 2023 · EClinicalMedicine
The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review
Suhui Qie, Ning Jiao, Kunfeng Duan, Jingxin Li, Yang Liu, Guoqiang Liu · 2021 · International Urology and Nephrology
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation
Jay B. Wish, Kai‐Uwe Eckardt, Csaba Pal Kovesdy, Steven N. Fishbane, Bruce Spinowitz, Jeffrey S. Berns · 2021 · American Journal of Kidney Diseases
Evolving therapies for lower-risk myelodysplastic syndromes
Jan Philipp Bewersdorf, Amer Methqal Zeidan · 2020 · Annals of Hematology
Anaemia of chronic diseases: Pathophysiology, diagnosis and treatment
Ricardo de las Cuevas Allende, Lucía Díaz de Entresotos, Susana Conde Díez · 2021 · Medicina Clínica (English Edition)
Transforming growth factor-β1 decreases erythropoietin production through repressing hypoxia-inducible factor 2α in erythropoietin-producing cells
Hong‐Mou Shih, Szu‐Yu Pan, Chih‐Jen Wu, Yu‐Hsiang Chou, Chun‐Yuan Chen, Fan‐Chi Chang, Yi‐Ting Chen, Wen‐Chih Chiang, Hsing-Chen Tsai, Yung‐Ming Chen et al. · 2021 · Journal of Biomedical Science
PHD2 deletion in endothelial or arterial smooth muscle cells reveals vascular cell type-specific responses in pulmonary hypertension and fibrosis
Harri Elamaa, Mika Kaakinen, Marjut Nätynki, Zoltán Szabó, Veli‐Pekka Ronkainen, Ville K. Äijälä, Joni M. Mäki, Risto Kerkelä, Johanna Myllyharju, Lauri Eklund · 2022 · Angiogenesis
Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
Tong Wu, Yuanyuan Qi, Shuang Ma, Lijie Zhang, Xinyu Pu, Kui Chen, Ying Zhao, Shenghua Sang, Jing Xiao · 2022 · Renal Failure
Rabeprazole Promotes Vascular Repair and Resolution of Sepsis-Induced Inflammatory Lung Injury through HIF-1α
Colin E. Evans, Yi Peng, Maggie M. Zhu, Zhiyu Dai, Xianming Zhang, You‐Yang Zhao · 2022 · Cells
Roxadustat: Do we know all the answers?
Qiuyu Li, Qian-Wen Xiong, Xuefeng Yao, Fei Liu, Xiaoxiao Tang, Haidong Fu, Tong Tong, Jianhua Mao, Wan‐Xin Peng · 2023 · Biomolecules and Biomedicine
Update of pericytes function and their roles in kidney diseases
Yu‐Hsiang Chou, Szu‐Yu Pan, Hong‐Mou Shih, Shuei‐Liong Lin · 2023 · Journal of the Formosan Medical Association
The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study
Weiwei Kong, Xiaoying Wu, Zhuowei Shen, Meifang Wang, Xinyu Liu, Xiaoli Lin, Yingyin Qiu, Hong Jiang, Jianghua Chen, Yan Lou et al. · 2024 · Kidney International Reports
Are all erythropoiesis-stimulating agents created equal?
Francesco Locatelli, Lucia Del Vecchio, Luca De Nicola, Roberto Minutolo · 2020 · Nephrology Dialysis Transplantation
Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia
Katsuyuki Miki, Yuki Nakamura, Takayoshi Yokoyama, Manabu Kamiyama, Yasuo Ishii · 2022 · Transplantation Proceedings
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD
Pablo E. Pérgola, Chaim Charytan, Dustin J. Little, Stefan Tham, Lynda Anne M. Szczech, Robert Leong, Steven N. Fishbane · 2022 · Kidney360
Role of hypoxia-inducible factor 1 in type 1 diabetes
Raphael R. Fagundes, Arnaud Zaldumbide, Cormac T. Taylor · 2024 · Trends in Pharmacological Sciences
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease
Piotr Bartnicki · 2024 · Biomedicines
Identification of novel plant cysteine oxidase inhibitors from a yeast chemical genetic screen
Mikel Lavilla-Puerta, Rebecca Latter, Francesca Bellè, Tiziana Cervelli, Alvaro Galli, Pierdomenico Perata A, Andrea Chini, Emily Flashman, Beatrice Giuntoli · 2023 · Journal of Biological Chemistry
Prolyl hydroxylase inhibitor FG-4592 alleviates neuroinflammation via HIF-1/BNIP3 signaling in microglia
Qianqian Ruan, Yanan Geng, Ming Zhao, Heyang Zhang, Xiang Cheng, Tong Zhao, Xiangpei Yue, Xiufang Jiang, Xiaoxia Jiang, Xiaoyu Hou et al. · 2024 · Biomedicine & Pharmacotherapy
Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
Dorien Groenendaal‐van de Meent, Virginie Kerbusch, Rüdiger Kaspera, Begona Barroso-Fernandez, Piergiorgio Galletti, Gernot Klein, Martin den Adel · 2020 · European Journal of Drug Metabolism and Pharmacokinetics
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Shaka Martin, Alina Jiletcovici, Frank Dellanna, Tadao Akizawa, Jonathan Barratt · 2024 · Advances in Therapy
Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression
Xiaodong Zhuang, Giulia Gallo, Parul Sharma, Jiyeon Ha, Andrea Magri, Helene Borrmann, James Michael Harris, Senko Tsukuda, Eleanor G. Bentley, Adam Kirby et al. · 2023 · iScience
HIF-1 contributes to autophagy activation via BNIP3 to facilitate renal fibrosis in hypoxia in vitro and UUO in vivo
Jing Liu, Man Jiang Livingston, Guie Dong, Qingqing Wei, Ming Zhang, Shuqin Mei, Jiefu Zhu, Chun Zhang, Zheng Dong · 2024 · American Journal of Physiology-Cell Physiology